CORRELATION BETWEEN CHRONIC SYSTEMIC INFLAMMATION, LIPID SPECTRUM, LIVER FUNCTION AND ANTIOXIDANT SYSTEM IN PATIENTS WITH COMORBID PATHOLOGY OF STABLE CORONARY HEART DISEASE WITH NONALCOHOLIC FATTY LIVER DISEASE

Manusha Yu. I., Goncharova O. O., Sakevich V. D., Chekalina N. I., Kazakov Yu. M.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The aim of the study was to examine the correlations between markers of chronic systemic inflammation (CHD), inflammatory endothelial activation, blood lipid spectrum, antioxidant system, liver and heart function in patients with stable coronary heart disease in combination with non-alcoholic fatty liver disease. The study involved 110 people with coronary heart disease: stable angina pectoris, II FC, CH 0-I in combination with non-alcoholic fatty liver disease aged 40-69 years. The analysis of indicators of a lipid spectrum of blood is made, studied the level of ceruloplasmin, cytokines (IL-6, TNFα, IL-10), circulating endothelial microparticles (CEM) CD32+ CD40+ in the blood, the expression of kappa B inhibitor mRNA gene α (IkBα) of nuclear kappa B transcription factor in peripheral blood mononuclear cells was studied and echocardiography, liver ultrasound with color and pulse Doppler imaging were performed (blood flow velocity in portal and hepatic veins was established). The relationship between the variables was then studied by correlation analysis. Conclusion. The correlation analysis established the relationship between the expression of mRNA IkBα nuclear transcription factor Kappa B with chronic systemic inflammation of low intensity, lipid metabolism with dysfunctional changes in blood flow in the liver (blood flow velocity in the portal vein), we can conclude that chronic systemic inflammation at the molecular genetic level plays an important role in the development of both coronary heart disease and nonalcoholic fatty liver disease and confirms the common pathogenetic mechanism of this comorbid pathology.

ischemic heart disease, nonalcoholic fatty liver disease, chronic systemic inflammation, dislipidemia, endothelial dysfunction, correlation.

1. Kovalenko VM, Kornatsʹkyy VM. Rehionalʹni medyko-sotsialʹni problemy khvorob systemy krovoobihu: dynamika ta analiz. Analitychnostatystychnyy posibnyk. Kyyiv; 2013. 240 s. [in Ukrainian].
2. Fadyeyenko HD, Chernyshov VA. Shlyakhy optymizatsiyi hipolipidemichnoyi terapiyi pry komorbidniy patolohiyi. Ukrayinsʹkyy terapevtychnyy zhurnal. 2012;2:123-6. [in Ukrainian].
3. Berezin AYe, Kruzlyak P. Tsirkuliruyushchiye endotelial’nyye apoptoticheskiye mikrochastitsy kak novyy marker kardiovaskulyarnogo riska. Ukrayinsʹkyy medychnyy chasopys. 2014;5(103):83-7. [in Russian].
4. Zaremba YeKh, Smalyukh OV. Markery zapalennya ta funktsiyi endoteliyu u khvorykh na ishemichnu khvorobu sertsya. Bukovynsʹkyy medychnyy visnyk. 2014;18(4(72):195-9. [in Ukrainian].
5. Zolotarʹova NA, Romanchenko MI. Endotelialʹna dysfunktsiya: diahnostychna znachushchistʹ, metody vyznachennya. Odesʹkyy medychnyy zhurnal. 2013;2:77-84. [in Ukrainian].
6. Manusha YuI, Kazakov YuM, Trybrat ТА, Ischeykin KYe. Peculiarities of systemiс inflammation of low intensity in patients with stable coronary heart disease concurrent with non-alcoholic fatty liver disease. Problemy ekolohiyi ta medytsyny. 2019;23(3-4):3-6.
7. Meng Q, Cooney M, Yepuri N, Cooney RN. L-arginine attenuates Interleukin-1β (IL-1β) induced Nuclear Factor Kappa-Beta (NF-κB) activation in Caco-2 cells. PLOS One. 2017;12(3):120-8.
8. Karpov AM, Rvacheva AV, Shogenova MKh. Sovremennyye predstavleniya ob immunovospalitel’nykh mekhanizmakh ateroskleroza. Ateroskleroz i dislipidemii. 2014;1:25-30. [in Russian].
9. Kravchenko AYa, Chernyayeva YuM. Rol’ tsitokinov v razvitii i techenii serdechnoy nedostatochnosti. Klinicheskaya meditsina. 2013;10:11- 6. [in Russian].
10. Ensan S, Li A, Besla Retal. Self-renewing resident arterial macrophages arise from embryonic CX3CR1(+) precursors and circulating monocytes immediately after birth. Nat. Immunol. 2016;17:159-68.
11. Manusha YuI, Kazakov YuM, Trybrat TA, Chekalina NI, Vakulenko KYe. Klinichnyy perebih ishemichnoyi khvoroby sertsya v umovakh komorbidnosti z nealkoholʹnoyu zhyrovoyu khvoroboyu pechinky. Aktualʹni problemy suchasnoyi medytsyny: Visnyk Ukrayinsʹkoyi medychnoyi stomatolohichnoyi akademiyi. 2019;19(3):52-6. [in Ukrainian].
12. Manusha YuI, Kazakov YuM. Vysvitlennya spilʹnykh patohenetychnykh mekhanizmiv rozvytku systemnoho zapalennya pry nealkoholʹniy zhyroviy khvorobi pechinky ta ishemichniy khvorobi sertsya. Aktualʹni problemy suchasnoyi medytsyny: Visnyk Ukrayinsʹkoyi medychnoyi stomatolohichnoyi akademiyi. 2017;17(3(59):277-81. [in Ukrainian].
13. Skybchyk VA, Voytovych MO. Nealkoholʹna zhyrova khvoroba pechinky: suchasna diahnostyka. Hepatolohiya. 2015;1:52-6. [in Ukrainian].
14. Unifikovanyy klinichnyy protokol «Nealkoholʹnyy steatohepatyt». Nakaz MOZ Ukrayiny № 826 vid 06.11.2014 r. [in Ukrainian].
15. Unifikovanyy klinichnyy protokol «Stabilʹna ishemichna khvoroba sertsya». Nakaz MOZ Ukrayiny № 152 vid 02.03.2016 r. [in Ukrainian].

«Bulletin of problems biology and medicine» Issue 3 (157), 2020 year, 118-121 pages, index UDK 616.127-005.4-06:616.36-003.826.[616-002-031.81+616-008.9]

10.29254/2077-4214-2020-3-157-118-121